Achmea Investment Management B.V. lessened its stake in shares of Zoetis Inc (NYSE:ZTS) by 21.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,747 shares of the company’s stock after selling 18,195 shares during the period. Achmea Investment Management B.V.’s holdings in Zoetis were worth $6,108,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Keybank National Association OH raised its holdings in Zoetis by 180.8% during the 2nd quarter. Keybank National Association OH now owns 199,773 shares of the company’s stock worth $17,019,000 after buying an additional 128,634 shares during the period. Chartwell Investment Partners LLC grew its stake in Zoetis by 7.0% during the 2nd quarter. Chartwell Investment Partners LLC now owns 76,888 shares of the company’s stock valued at $6,550,000 after acquiring an additional 5,000 shares in the last quarter. Milestone Resources Group Ltd grew its stake in Zoetis by 2.2% during the 3rd quarter. Milestone Resources Group Ltd now owns 1,089,644 shares of the company’s stock valued at $99,768,000 after acquiring an additional 23,730 shares in the last quarter. FMR LLC grew its stake in Zoetis by 26.3% during the 2nd quarter. FMR LLC now owns 1,654,795 shares of the company’s stock valued at $140,972,000 after acquiring an additional 344,241 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Zoetis by 8.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock valued at $448,309,000 after acquiring an additional 422,856 shares in the last quarter. Hedge funds and other institutional investors own 89.68% of the company’s stock.
Several equities analysts have weighed in on ZTS shares. Stifel Nicolaus lifted their target price on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Morgan Stanley lifted their target price on Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research note on Friday, August 3rd. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the company a “buy” rating in a research note on Friday, July 27th. JPMorgan Chase & Co. lifted their target price on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. Finally, Jefferies Financial Group set a $96.00 target price on Zoetis and gave the company a “buy” rating in a research note on Friday, July 13th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $93.19.
In related news, insider Catherine A. Knupp sold 46,816 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total value of $4,252,765.44. Following the completion of the sale, the insider now owns 81,640 shares of the company’s stock, valued at approximately $7,416,177.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Juan Ramon Alaix sold 135,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total value of $12,359,250.00. The disclosure for this sale can be found here. In the last three months, insiders sold 350,507 shares of company stock valued at $32,579,830. 0.35% of the stock is currently owned by company insiders.
Shares of NYSE ZTS opened at $95.27 on Friday. The company has a market capitalization of $44.57 billion, a P/E ratio of 39.70, a PEG ratio of 1.83 and a beta of 0.97. Zoetis Inc has a 52 week low of $68.56 and a 52 week high of $96.57. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.06. The business had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.65 EPS. As a group, equities analysts forecast that Zoetis Inc will post 3.11 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Tuesday, November 20th will be paid a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.53%. Zoetis’s payout ratio is 20.83%.
WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/11/10/zoetis-inc-zts-holdings-cut-by-achmea-investment-management-b-v.html.
Zoetis Company Profile
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Featured Article: The risks of owning bonds
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.